Compare Quest Diagnostics Inc (DGX) vs Enbridge Inc (ENB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Enbridge Inc — how do they compare? Quest Diagnostics Inc trades at $231.12 (market cap $25.48B), while Enbridge Inc trades at $46.45 (market cap $103.38B). The key difference: Enbridge Inc is far larger — about 4.1× Quest Diagnostics Inc's market cap, and Enbridge Inc pays the higher dividend (6.02%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Enbridge Inc for 91 Days on average.
| DGX | ENB | |
|---|---|---|
Market Cap | $25.48B | $103.38B |
Volume | 941,866 | 3,684,305 |
Sector | Health | Energy |
52-Week High | $247.45 | $58.04 |
52-Week Low | $173.49 | $45.23 |
Typical Hold Time | 56 Days | 91 Days |
Enterprise Value | $31.23B | $185.39B |
Dividend Yield | 1.49% | 6.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
ENB trades at $45.89, down 1.4% on the day, with a bearish technical signal but strong recent earnings beats. The company posted $65.19B in 2025 revenue, with net income of $7.49B and a 7.34% margin. Analysts maintain a consensus buy rating with a $61.63 price target, highlighting a 6% dividend yield and robust cash flow from operations of $12.27B.
Outlook is positive due to consistent EBITDA growth, a $41B project backlog, and defensive midstream assets, though risks include high debt levels and sensitivity to interest rates. The stock offers value with a P/E of 25.54 and P/S of 1.73, supported by institutional interest and dividend stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →
